US equities |
TSLA $395.95 ▲+6.38% MU $904.01 ▲+3.02% SPCX $148.56 ▲+0.73% NVDA $217.09 ▲+2.90% META $644.69 ▲+0.32% SNDK $1,260.27 ▲+1.80% AAPL $346.58 ▼-0.33% AMD $526.22 ▲+1.82%
FinancialContent

Metagenomi Therapeutics, Inc. - Common Stock (NQ:MGX)

0.8000 -0.0056 (-0.70%)
Delayed Quote Updated: 10:59 AM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Metagenomi Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Metagenomi, Inc. (MGX) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Metagenomi, Inc. (MGX)
From Kirby McInerney LLP
Via Business Wire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Metagenomi, Inc. (MGX) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Metagenomi, Inc. (MGX) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Metagenomi to Present at the 2024 Jefferies Global Healthcare Conference
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
MGX Stock Earnings: Metagenomi Misses EPS, Beats Revenue for Q1 2024 ↗
MGX stock results show that Metagenomi missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars ↗
Moderna reports Q1 loss, beating sales estimates amidst declining COVID-19 vaccine demand. Cost-saving measures drive optimism for investors. CEO Stéphane Bancel eyes strategic investments. Guidance... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire ↗
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion. 
Via InvestorPlace
News headline image
Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems
Enhances strategic flexibility and control of key gene editing technologies and programs 
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Metagenomi to Present at Upcoming Scientific Meetings
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Reports Business Updates and Full Year 2023 Financial Results
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference
From Metagenomi Technologies, LLC
Via GlobeNewswire
News headline image
This Biotech IPO Stock Just Took a Tumble, But Don't Give Up on It Yet ↗
A bumpy start can't detract from this company's strong balance sheet. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Metagenomi Announces Closing of Initial Public Offering
From Metagenomi Technologies, LLC
Via GlobeNewswire
News headline image
Gilead-Backed Kyverna Overshoots Raised IPO Expectations ↗
Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a... 
Via Talk Markets
Topics Initial Public Offering
< Previous 1 2 3 4 5 Next >